EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies

Hannelore I Coerts, Bart de Keizer, Robert J Marlowe, Frederik A Verburg iD

European Journal of Endocrinology · 2023

DOI: 10.1093/ejendo/lvad006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Hannelore I Coerts und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, 3015 GD, The Netherlands. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyrotropin Alfa, Hypothyroidism. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: Dutch Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients undergoing radioiodine therapy (RIT) of differentiated thyroid carcinoma (DTC), thyroid-stimulating hormone (TSH) stimulation prior to RIT can be achieved using thyroid hormone withdrawal (THW) or administration of recombinant human TSH (rhTSH). As THW can lead to nausea, headaches, vomiting, fatigue, and dizziness secondary to transient acute hypothyroidism, rhTSH could be a good alternative. Recombinant human TSH has been administered in patients in order to stimulate TSH for RIT since 2005. According to the Martinique criteria formulated by the leading professional societies involved in care of patients with DTC, rhTSH can be applied in 3 settings: for remnant ablation, adjuvant treatment, and treatment of known disease. Numerous studies have investigated the effects of rhTSH as a method of TSH stimulation on the thyroid cell, the systemic effects, biokinetics, and clinical outcomes; however, no consensus has been reached about many aspects of its potential use. Recombinant human TSH is able to stimulate sufficient TSH levels (>30 mIU L–1) and is hypothesized to decrease risks of tumor cell proliferation. As rhTSH-use avoids the transiently impaired renal function associated with THW, radioiodine excretion is faster with the former, leading to a lower iodine-131 uptake and a difference in fractional remnant uptake, effective half-life, mean residence time, and dose to the blood. Differences between rhTSH and THW were observed in radioiodine genotoxic effects and endothelial-dependent vasodilation and inflammation. For thyroid remnant ablation, THW and rhTSH lead to similar remnant ablation rates. For adjuvant therapy and treatment of known disease, insufficient trials have been conducted and future prospective studies are recommended. The current review provides a state-of-the-science overview on the issues and debates surrounding TSH stimulation through either rhTSH adminsitration orendogenous TSH production after levothyroxin withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyrotropin AlfaHypothyroidismHumansThyrotropinIodine RadioisotopesProspective StudiesThyroid HormonesRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

radioactive iodinerecombinant human TSHthyroid hormone withdrawal

Substanzen

ThyrotropinIodine RadioisotopesThyrotropin AlfaThyroid HormonesRecombinant Proteins

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, 3015 GD, The Netherlands.
  • Department of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, 3584 CX, The Netherlands.
  • Spencer-Fontayne Corp., Jersey City, NJ 07304-1901, United States.

ORCID-Profile: Frederik A Verburg

Förderung

  • Dutch Cancer Foundation

Zitieren

APA

Coerts, H. I., de Keizer, B., Marlowe, R. J., & Verburg, F. A. (2023). Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad006

Vancouver

Coerts HI, de Keizer B, Marlowe RJ, Verburg FA. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvad006

BibTeX
@article{Coerts2023,
  author = {Coerts, Hannelore I and de Keizer, Bart and Marlowe, Robert J and Verburg, Frederik A},
  title = {Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies},
  journal = {European Journal of Endocrinology},
  year = {2023},
  doi = {10.1093/ejendo/lvad006}
}
Kostenlos starten →